Samsung Medical Center

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Subsidiary

Established: 1994-01-01

Employees: 501

Market Cap: -

Website: http://www.samsunghospital.com

Clinical Trials

Usual Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin on Coronary Atherosclerotic Plaque

Phase 4

Active, not recruiting

Conditions: Coronary Artery Disease

Interventions: Drug: Rosuvastatin 20 mg orally once a day
Drug: Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day

First Posted Date: 2017-05-30

Last Posted Date: 2024-04-22

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 280

Registration Number: NCT03169985

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy

Phase 2

Withdrawn

Conditions: Solid Tumor

First Posted Date: 2017-05-25

Last Posted Date: 2019-05-20

Lead Sponsor: Samsung Medical Center

Registration Number: NCT03166176

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy

Phase 2

Withdrawn

Conditions: Solid Tumor

Interventions: Drug: Vistusertib(AZD2014)

First Posted Date: 2017-05-25

Last Posted Date: 2019-05-20

Lead Sponsor: Samsung Medical Center

Registration Number: NCT03166904

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Serum BDNF Role as a Biomarker for Stroke Rehabilitation

Completed

Conditions: Biomarker
BDNF
Stroke
Rehabilitation

First Posted Date: 2017-05-24

Last Posted Date: 2020-03-18

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 150

Registration Number: NCT03164798

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib

Phase 2

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Pembrolizumab

First Posted Date: 2017-05-23

Last Posted Date: 2022-08-08

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 60

Registration Number: NCT03163992

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes

Phase 2

Completed

Conditions: Neuroendocrine Carcinoma, Grade 3

Interventions: Drug: Avelumab

First Posted Date: 2017-05-10

Last Posted Date: 2019-12-30

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 14

Registration Number: NCT03147404

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

The Efficacy and Safety of Udenafil in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy

Phase 4

Conditions: Prostate Cancer With Radical Prostatectomy

Interventions: Drug: ZYDENA TAB.75mg(Udenafil 75mg)
Drug: Placebo Oral Tablet

First Posted Date: 2017-05-05

Last Posted Date: 2017-05-05

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 99

Registration Number: NCT03142542

Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX

Phase 4

Completed

Conditions: Metastatic Non-Small Cell Lung Carcinoma

Interventions: Drug: Pembrolizumab Injection

First Posted Date: 2017-05-01

Last Posted Date: 2024-12-03

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 50

Registration Number: NCT03134456

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Young Breast Cancer Cohort Study

Conditions: Breast Cancer

First Posted Date: 2017-04-27

Last Posted Date: 2017-04-27

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 2000

Registration Number: NCT03131089

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold

Phase 4

Terminated

Conditions: Coronary Artery Disease
Atherosclerosis
Stents

Interventions: Drug: Clopidogrel
Drug: Ticagrelor
Drug: Aspirin

First Posted Date: 2017-04-18

Last Posted Date: 2024-04-22

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 25

Registration Number: NCT03119012

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy